-
Nitrocefin: From β-Lactamase Signal to Translation
2026-08-13
Nitrocefin converts β-lactamase hydrolysis into a rapid yellow-to-red signal, giving translational researchers a practical bridge between enzyme mechanism, resistance profiling, inhibitor discovery, and computational peptide screening. This article outlines how to interpret the assay beyond a simple color change and how to position it within a rigorous development workflow.
-
Decitabine Primes Progenitor Tex for PD-1 Blockade
2026-08-13
A 2023 Journal of Clinical Investigation study shows that low-dose decitabine can improve anti–PD-1 therapy by expanding CD8+ progenitor exhausted T cells rather than merely reactivating terminally exhausted cells. The work identifies sustained JunD and JNK/AP-1 activity as an important mechanistic link and offers a framework for evaluating epigenetic priming in tumor-immunology models.
-
Dextrose Workflows for Hypoxic Tumor Research
2026-08-12
Build controlled hypoxia–nutrient experiments with Dextrose (D-glucose), from fresh stock preparation to immune–tumor co-culture readouts. This workflow emphasizes matched controls, practical concentration matrices, and troubleshooting strategies that distinguish glucose effects from oxygen, osmotic, and handling artifacts.
-
Angiotensin (1-7): Applied Research Workflows
2026-08-12
Build reproducible Mas-receptor, fibrosis, inflammation, metabolic, and peptide–receptor-binding assays around a high-purity endogenous heptapeptide. This guide connects literature-backed benchmarks with practical stock preparation, dose selection, assay controls, and troubleshooting for translational research.
-
Dihydrotestosterone: From AR Trigger to Assay Design
2026-08-11
Dihydrotestosterone (DHT) is a precise androgen receptor perturbation tool for studying transcription, EGFR–ERBB2 signaling, and muscle phenotypes. This guide connects product handling with evidence-based assay decisions and insights from a recent prostate biology study.
-
Sulfo-NHS-LC-Biotin: Practical Labeling Guide
2026-08-11
Sulfo-NHS-LC-Biotin is a water-soluble reagent for stable biotin labeling of accessible primary amines on proteins, peptides, and intact-cell surfaces. It is suited to aqueous cell-surface and protein workflows using biotin-avidin or streptavidin capture, but not to reversible labeling or intracellular labeling of cells with intact plasma membranes.
-
GOB-38 in Elizabethkingia anophelis: Evidence and Methods
2026-08-10
The reference study characterizes GOB-38, a B3-Q metallo-β-lactamase from Elizabethkingia anophelis, by combining genomic analysis, recombinant expression, biochemical profiling, and co-culture experiments. Its findings connect broad β-lactam hydrolysis and an unusual active-site composition with clinically important resistance and the possible exchange of carbapenem resistance during polymicrobial infection.
-
MDockPeP2_VS: Screening Peptide Inhibitors
2026-08-09
Xu and colleagues introduce MDockPeP2_VS, a structure-based peptide-screening strategy that reduces conformational search by using conservation between protein folding and protein–peptide binding. In a TEM-1 β-lactamase demonstration, the workflow identified TF7 as an inhibitory peptide with a reported Ki of 1.37 ± 0.37 μM, providing a practical starting point for peptide-based antibiotic resistance research.
-
MLKL Polymerization and Cathepsin B in Necroptosis
2026-08-08
The reference study identifies lysosomal membrane permeabilization as a decisive intermediate between MLKL polymerization and plasma membrane rupture during necroptosis. Its imaging, perturbation, and MLKL-domain experiments support a model in which lysosomal release of cathepsin B helps execute cell death, creating a defined experimental framework for studying lysosome–protease mechanisms.
-
FAK Inhibitor 14: From EMT Mechanism to Translation
2026-08-07
A translational framework for using FAK Inhibitor 14 to interrogate PARP1/FAK/COL5A1 signaling, EMT, and migration in cholesterol-resistant ovarian cancer models.
-
MDL 28170: Next-Generation Calpain Inhibition for Translatio
2026-08-07
This thought-leadership article examines the mechanistic underpinnings and translational strategies for targeting calpain-mediated pathology, anchored by new evidence linking MDL 28170 to neurodevelopmental protection and cognitive rescue. By integrating breakthrough findings, advanced protocol guidance, and a critical view of the competitive landscape, the article delivers actionable insights for researchers designing high-impact neuroprotection, apoptosis, and ischemia-reperfusion injury models.
-
Genistein: Applied Workflows in Cancer Chemoprevention Resea
2026-08-06
Genistein (5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one) stands out for its selective inhibition of protein tyrosine kinases, providing robust and reproducible control over cell proliferation and oncogenic signaling. This article delivers a protocol-driven perspective, bridging the latest mechanotransduction insights with practical troubleshooting strategies for cancer chemoprevention, apoptosis assays, and cytoskeleton-dependent research.
-
Quinolone–Coumarin Hybrids and Novobiocin Against T. gondii
2026-08-06
This study evaluates novel quinolone–coumarin hybrids, synthesized from fluoroquinolones and Novobiocin, for their in vitro effectiveness against Toxoplasma gondii. The results identify several hybrids and Novobiocin itself as promising anti-parasitic candidates with high selectivity and minimized toxicity to host cells, offering new directions for anti-Toxoplasma drug development.
-
Optimizing DNA Damage Assays with Rucaparib (AG-014699, PF-0
2026-08-05
This scenario-driven guide evaluates real laboratory challenges in DNA damage response research and demonstrates how Rucaparib (AG-014699, PF-01367338), SKU A4156, elevates reliability, sensitivity, and workflow reproducibility. By integrating best practices and recent literature, we provide actionable insights for bench scientists seeking robust PARP1 inhibition and radiosensitization in cancer biology research.
-
MDL 28170: Advancing Calpain Inhibition for Translational Im
2026-08-05
This thought-leadership article explores the mechanistic and translational value of selective calpain inhibition using MDL 28170, uniting recent neurodevelopmental insights with actionable workflow guidance. By framing the biopathological rationale, reviewing experimental validation, and situating MDL 28170 within the broader research landscape, we offer strategic perspectives for translational researchers navigating neuroprotection, apoptosis, and cross-domain disease models.